Prescription Drug Monitoring Act of 2019
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Prescription Drug Monitoring Act of 2019
This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.
The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.
Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 3974: Prescription Drug Monitoring Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-3974/
"H.R. 3974: Prescription Drug Monitoring Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-3974/.
H.R. 3974, 116th Cong. (2026), https://openamerica.io/bill/116-HR-3974/.
[H.R. 3974: Prescription Drug Monitoring Act of 2019](https://openamerica.io/bill/116-HR-3974/)